1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

BMS’s Mezigdomide Myeloma Data Give Glimpse Of CELMoD Future

Phase I/II Results Published In NEJM

 
• By Alaric DeArment

The trial’s principal investigator said the goal is to establish mezigdomide for use in patients who have failed on Pomalyst. BMS is running a head-to-head trial of both drugs.

BMS published data from its Phase I/II study of mezigdomide in the New England Journal of Medicine • Source: Shutterstock

Published Phase I/II data for Bristol Myers Squibb Company’s mezigdomide bolster the case for the drug’s activity and safety in heavily pretreated multiple myeloma patients, particularly those who have received prior BCMA-directed therapies. The results also hint at where the drug could end up fitting into treatment, with patients who have failed on BMS’s Pomalyst (pomalidomide) being an attractive target population.

Results of the study of mezigdomide combined with dexamethasone in triple-class refractory patients appeared online 30 August in the New...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from Therapy Areas

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.